Cochlear agrees to acquire Oticon Medical, Demant's hearing implants business

27 April 2022

Cochlear Limited, a global leader in implantable hearing solutions, agrees to acquire Oticon Medical for DKK850 million (approx. AUD170 million) following Demant’s decision to exit its hearing implants business activities. As part of the transaction, Cochlear has committed to providing ongoing support for Oticon Medical’s base of more than 75,000 hearing implant recipients, which includes cochlear and acoustic implants.

Cochlear's CEO & President, Dig Howitt said, "We look forward to welcoming Oticon Medical's implant customers to the Cochlear family. Driven by our mission to innovate and deliver a lifetime of hearing outcomes, we will seek to ensure that Oticon Medical's customers continue to be supported with a lifetime of hearing solutions. We will work closely with Demant to ensure a seamless transition, with continued access to current Oticon Medical technology for customers in the coming years. We will develop next generation sound processors and services that will enable customers to transition to and benefit from Cochlear's technology platform over time.

"The acquisition of Oticon Medical will provide us with greater scale and will enable us to increase our investments in R&D and market growth activities. While Cochlear is a market leader in implantable hearing, we are a small player in the hearing loss segment where hearing aids remain the primary treatment option. Our goal is to improve the penetration of implantable hearing solutions, building customer awareness and confidence, and offering more patients hearing solutions best suited to their individual needs.

"Oticon Medical is expected to add AUD75‐80 million to annual revenue. The business is currently loss making. Our priority post‐closing of the transaction will be to determine and implement a plan that returns the business to profitability as quickly as possible. Integration costs, which include the development of compatible next generation sound processors, are yet to be determined and could range from $30‐60 million. We continue to target a long‐term net profit margin of 18%."

To comply with French labour law requirements, the proposed transaction will be subject to a mandatory consultation process with Oticon Medical's Nice‐based employee works council. Completion of the transaction will be conditional on satisfaction of customary closing conditions and receipt of competition approvals in jurisdictions where the transaction meets relevant notification thresholds. The acquisition will be funded from existing cash balances and is expected to close in the second half of 2022. Cochlear will not be assuming any liability for issues that may arise from the voluntary field corrective action for Oticon Medical's Neuro Zti cochlear implant announced in October 2021.

For further information, please contact:
Kristina Devon
Vice President, Investor Relations
Phone: (+61) 2 9611 6691

Jennifer Stevenson
Vice President, Communications & Brand
Phone: (+61) 2 9611 6959

This announcement is authorised by the Cochlear Board of Directors.

Vyloučení odpovědnosti

O způsobech léčby ztráty sluchu se poraďte se svým odborným zdravotníkem. Výsledky léčby se mohou lišit a váš odborný zdravotník vám vysvětlí, jaké faktory by je mohly ovlivnit ve vašem případě. Vždy se řiďte pokyny k používání. Některé produkty nemusí být dostupné ve všech zemích. Informace o produktech vám poskytne místní zástupce společnosti Cochlear.